Evaluation of ivabradine plus beta-blocker versus beta-blocker alone in addition to standard care in reducing...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Increasing incidence of heart failure (HF) leading to higher hospitalization rates and cardiovascular mortality.
• Need for effective therapeutic strategies for chronic HF patients with reduced left ventricular ejection fraction (LVEF).

Purpose of the Study:

• To evaluate the efficacy of ivabradine plus beta-blocker (IVA+BB) versus beta-blocker alone (BB) in patients with chronic HF and LVEF < 35%.
• To assess the impact on hospitalization rates and major adverse cardiovascular events (MACE) over a 6-month period.

Main Methods:

• Observational study including 64 patients with LVEF < 35%.
• Two groups: 30 patients in IVA+BB group and 34 patients in BB group.
• Primary endpoint: composite MACE (MI, stroke, death, worsening HF). Secondary endpoints: heart rate, NYHA class, MLWHFQ.

Main Results:

• No significant difference in composite MACE incidence between the groups (5 events in each).
• Mean heart rate significantly decreased from baseline in the IVA+BB group at 3 and 6 months (p<0.001).
• Heart rate significantly increased in the BB group at 3 months (p<0.01) and 6 months (p<0.05).
• No significant changes observed in NYHA class or MLWHFQ scores.

Conclusions:

• IVA+BB combination therapy was well-tolerated in the study population.
• IVA+BB demonstrated a trend towards a smaller decrease in hospitalizations and a delay in MACE events compared to BB alone.
• Further research with larger sample sizes is warranted, particularly within the Indian population.